The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
The convalescent sera option for containing COVID-19
Open accessAbstract
As of early 2020, humanity is confronting a pandemic in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).SARS-CoV-2 causes coronavirus disease, abbreviated as COVID-19.At the time of this writing, SARS-CoV-2 is spreading in multiple countries, threatening a pandemic that will affect billions of people.This virus appears to be a new human pathogen.Currently there are no vaccines, monoclonal antibodies (mAbs), or drugs available for SARS-CoV-2, although many are in rapid development and some may be available in a short time.This Viewpoint argues that human convalescent serum is an option for prevention and treatment of COVID-19 disease that could be rapidly available when there are sufficient numbers of people who have recovered and can donate immunoglobulin-containing serum.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L. E., Davey, R. T., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,605
Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P., Khaw, F.-M., Lim, W. S., Makki, S., Rooney, K. D., Convalescent Plasma Study Group, Nguyen-Van-Tam, J. S., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu396 · Cited by 983
Use of convalescent plasma therapy in SARS patients in Hong Kong
Cheng, Y., Wong, R., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., Chan, P., Wong, K. C., Leung, C. B., & Cheng, G. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1271-9 · Cited by 958
Hung, I. F., To, K. K., Lee, C.-K., Lee, K.-L., Chan, K., Yan, W.-W., Liu, R., Watt, C.-L., Chan, W.-M., Lai, K.-Y., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq106 · Cited by 678
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
Wan, Y., Shang, J., Sun, S., Tai, W., Chen, J., Geng, Q., He, L., Chen, Y., Wu, J., Shi, Z., et al. (2020) · Journal of Virology · doi:10.1128/jvi.02015-19 · Cited by 662
Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?
Luke, T. C., Kilbane, E. M., Jackson, J. L., & Hoffman, S. L. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00139 · Cited by 636
Passive antibody therapy for infectious diseases
Casadevall, A., Dadachova, E., & Pirofski, L.-A. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro974 · Cited by 531
Self-citationTransfusion-related Acute Lung Injury in the Critically Ill: Prospective Nested Case-Control Study
Gajic, O., Rana, R., Winters, J. L., Yilmaz, M., Mendez, J. L., Rickman, O. B., O'Byrne, M. M., Evenson, L. K., Malinchoc, M., DeGoey, S. R., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200702-271oc · Cited by 430
Treatment with Convalescent Plasma for Influenza A (H5N1) Infection
Zhou, B., Zhong, N., & Guan, Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070359 · Cited by 406
Robbins, J. B., Schneerson, R., & Szu, S. C. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1387 · Cited by 385
Ko, J.-H., Seok, H., Cho, S. Y., Ha, Y. E., Baek, J. Y., Kim, S. H., Kim, Y.-J., Park, J. K., Chung, C. R., Kang, E.-S., et al. (2018) · Antiviral Therapy · doi:10.3851/imp3243 · Cited by 323
Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases
Casadevall, A., & Scharff, M. D. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.1.150 · Cited by 318
Self-citationFc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease
van Erp, E. A., Luytjes, W., Ferwerda, G., & van Kasteren, P. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00548 · Cited by 281
Serum therapy revisited: animal models of infection and development of passive antibody therapy
Casadevall, A., & Scharff, M. D. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.8.1695 · Cited by 251
Self-citationYeh, K.-M., Chiueh, T.-S., Siu, L. K., Lin, J.-C., Chan, P. K. S., Peng, M.-Y., Wan, H.-L., Chen, J.-H., Hu, B.-S., Perng, C.-L., et al. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki346 · Cited by 247
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia
Arabi, Y. M., Hajeer, A. H., Luke, T., Raviprakash, K., Balkhy, H., Johani, S., Al-Dawood, A., Al-Qahtani, S., Al-Omari, A., Al-Hameed, F., et al. (2016) · Emerging Infectious Diseases · doi:10.3201/eid2209.151164 · Cited by 244
A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus
Gunn, B. M., Yu, W.-H., Karim, M. M., Brannan, J. M., Herbert, A. S., Wec, A. Z., Halfmann, P. J., Fusco, M. L., Schendel, S. L., Gangavarapu, K., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.07.009 · Cited by 218
Kraft, C. S., Hewlett, A. L., Koepsell, S., Winkler, A. M., Kratochvil, C. J., Larson, L., Varkey, J. B., Mehta, A. K., Lyon, G. M., Friedman-Moraco, R. J., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ334 · Cited by 195
Antibody-mediated regulation of cellular immunity and the inflammatory response
Casadevall, A., & Pirofski, L.-A. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00228-x · Cited by 168
Self-citationHark back: Passive immunotherapy for influenza and other serious infections
Luke, T. C., Casadevall, A., Watowich, S. J., Hoffman, S. L., Beigel, J. H., & Burgess, T. H. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181d44c1e · Cited by 150
Self-citationEvaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone
Sahr, F., Ansumana, R., Massaquoi, T. A., Idriss, B. R., Sesay, F. R., Lamin, J. M., Baker, S., Nicol, S., Conton, B., Johnson, W. R., et al. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.11.009 · Cited by 121
Beigel, J. H., Voell, J., Kumar, P., Raviprakash, K. S., Wu, H., Jiao, J., Sullivan, E. J., Luke, T. C., & Davey, R. T. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30002-1 · Cited by 115
Crowe, J. E., Firestone, C.-Y., & Murphy, B. R. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.7.3910 · Cited by 113
A serological survey on neutralizing antibody titer of SARS convalescent sera
Zhang, J.-S., Chen, J.-T., Liu, Y.-X., Zhang, Z.-S., Gao, H., Liu, Y., Wang, X., Ning, Y., Liu, Y.-F., Gao, Q., et al. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20431 · Cited by 93
Jenks, J. A., Goodwin, M. L., & Permar, S. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02110 · Cited by 75
Successful treatment of avian influenza with convalescent plasma.
Kong, L.-B., & Zhou, B. P. (2006) · PubMed · Cited by 73
Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma
Wu, X., Gao, H., Wu, H., Peng, X., Ou, H., & Li, L. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2015.10.009 · Cited by 54
Cited by
Fair Allocation of Scarce Medical Resources in the Time of Covid-19
Emanuel, E. J., Persad, G., Upshur, R., Thome, B., Parker, M., Glickman, A., Zhang, C., Boyle, C., Smith, M., & Phillips, J. P. (2020) · New England Journal of Medicine · doi:10.1056/nejmsb2005114 · Cited by 3,137
Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E., Oczkowski, S., Levy, M. M., Derde, L., Dzierba, A., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06022-5 · Cited by 2,105
Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E., Oczkowski, S., Levy, M. M., Derde, L., Dzierba, A., et al. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004363 · Cited by 1,565
Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19
Azkur, A. K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M., O’Mahony, L., Gao, Y., Nadeau, K., & Akdis, C. A. (2020) · Allergy · doi:10.1111/all.14364 · Cited by 1,119
Bhimraj, A., Morgan, R. L., Shumaker, A. H., Lavergne, V., Baden, L., Cheng, V. C.-C., Edwards, K. M., Gandhi, R., Muller, W. J., O’Horo, J. C., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa478 · Cited by 1,033
Metadata
- Authors
- Casadevall, A., & Pirofski, L.-A.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-03-13
- Volume
- 130
- Issue
- 4
- Pages
- 1545-1548
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3011379523
- Cited by
- 903
- References
- 27
- FWCI
- 25.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.